CRISPR Therapeutics: Early Autoimmune Promise, Best-in-Class Oncology Data, and Eli Lilly Partnership Support Buy Rating
I'm PortAI, I can summarize articles.
William Blair analyst Sami Corwin maintains a Buy rating on CRISPR Therapeutics, citing promising autoimmune and oncology data, and a strategic partnership with Eli Lilly. The zugo-cel results show potential in autoimmune cases and best-in-class response rates in lymphoma. The Eli Lilly collaboration could enhance strategic opportunities. H.C. Wainwright also reiterates a Buy rating with an $80 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments